
Active Motif (AKA: The Active Motif Inc) Profile last edited on: 1/4/22
CAGE: 3UXL3
UEI: N7GVF5GCF3A6
Business Identifier: Fluorescent reagents for Life Science research applications Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Multiple
Congr. District: 49
County: San Diego
Congr. District: 49
County: San Diego
Public Profile
A global company built by scientists for scientists, for two decades Active Motif personnel have been developing groundbreaking technologies, products, and services for epigenetics and gene regulation research. The effort is to develop and distribute cell biology-based research tools and bio-computing resources for epigenetics and gene regulation research. With tools designed to assist in determining the functions, interactions, and regulation of genes and their encoded proteins, the firm also offers products for transcriptional regulation; epigenetics and chromatin; antibodies; protein detection and quantitation; recombinant proteins and enzymes; cell, acid, and tissue extracts; fluorescence; sample preparation; transfection and expression; and epigenetics services and bioinformatic applications. Serving life scientists from academic and government institutions, biotechnology and pharmaceutical companies, hospitals, and reference laboratories, products through distributors in the US and internationally, the firm is headqquaretred in Carlsbad CA., having also offices in Lake Placid, NY; La Hulpe, Belgium; and Tokyo, Japan.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
75-99Revenue Range
7.5M-10MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
20-24Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2024 | 1 | NIH | $314,262 | |
Project Title: Novel Integrated Platform to Quantitate Rejuvenation in vivo | ||||
2020 | 2 | NIH | $2,097,255 | |
Project Title: Epi-Seq: Multiplexed ChIP-Seq for Personalized Medicine and Drug Discovery | ||||
2017 | 1 | NIH | $225,000 | |
Project Title: FFPE histone enrichment for antibody and mass spectrometry analysis of post translational modifications in epigenetic biomarker discovery | ||||
2016 | 1 | NIH | $225,000 | |
Project Title: Method for De Novo Discovery of Locus Specific Regulatory Elements | ||||
2016 | 1 | NIH | $224,995 | |
Project Title: Multi-Epitope Tag (Met)-Recombinant Antibody Toolbox for Detection and Manipulation of Rna Modifications |
Key People / Management
Theodore DeFrank -- President and CEO
Joseph Fernandez -- Founder and Chair
Dorothy M Archdeacon
John Archdeacon -- Former Head of Research and Development
Barton Challis
Brian Egan -- Vice President of Operation
Fritz Eibel -- SVP of Global Sales & Corporate Development
Mary Anne Jelinek
Theresa K Kelly -- R&D Director
Herve Le Calvez
Gary Shiels -- Vice President of Marketing
Steve Stelman -- Director of IT and Bioinformatics
Jacques Weissman
Patrick Yount -- Chief Financial Officer
Joseph Fernandez -- Founder and Chair
Dorothy M Archdeacon
John Archdeacon -- Former Head of Research and Development
Barton Challis
Brian Egan -- Vice President of Operation
Fritz Eibel -- SVP of Global Sales & Corporate Development
Mary Anne Jelinek
Theresa K Kelly -- R&D Director
Herve Le Calvez
Gary Shiels -- Vice President of Marketing
Steve Stelman -- Director of IT and Bioinformatics
Jacques Weissman
Patrick Yount -- Chief Financial Officer